Pharma innovators will welcome SCOTUS decision to tackle 102 uncertainty; but must wait for 101 guidance

Pharma innovators will welcome SCOTUS decision to tackle 102 uncertainty; but must wait for 101 guidance

The US Supreme Court’s treatment of patentability in recent times has often been frustrating to life sciences innovators, with last month’s refusal to grasp the nettle of patent eligible subject matter in Cleveland Clinic Foundation v True Health…

Unlock unlimited access to all IAM content